- Introduction
- Global Markets Direct Report Coverage
- Graft Versus Host Disease (GVHD) Overview
- Therapeutics Development
- Pipeline Products for Graft Versus Host Disease (GVHD) - Overview
- Pipeline Products for Graft Versus Host Disease (GVHD) - Comparative Analysis
- Graft Versus Host Disease (GVHD) - Therapeutics under Development by Companies
- Graft Versus Host Disease (GVHD) - Therapeutics under Investigation by Universities/Institutes
- Graft Versus Host Disease (GVHD) - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Unknown Stage Products
- Graft Versus Host Disease (GVHD) - Products under Development by Companies
- Graft Versus Host Disease (GVHD) - Products under Investigation by Universities/Institutes
- Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development
- AbbVie Inc.
- AbGenomics International, Inc.
- Actelion Ltd
- Adienne Pharma & Biotech
- Alexion Pharmaceuticals, Inc.
- Apceth GmbH & Co. KG
- Athersys, Inc.
- Bellicum Pharmaceuticals, Inc.
- Bio-Cancer Treatment International Limited
- Biogen, Inc.
- Bristol-Myers Squibb Company
- Caladrius Biosciences, Inc.
- Cell2B S.A.
- CytoDyn Inc.
- Dr. Falk Pharma GmbH
- Enlivex Therapeutics Ltd
- Escape Therapeutics, Inc.
- F. Hoffmann-La Roche Ltd.
- Generon (Shanghai) Corporation Ltd.
- GlaxoSmithKline Plc
- Idera Pharmaceuticals, Inc.
- ImmuNext, Inc.
- Immunomedics, Inc.
- Jazz Pharmaceuticals Plc
- Kadmon Corporation, LLC
- Kamada Ltd.
- Kiadis Pharma B.V.
- Kymab Limited
- MacroGenics, Inc.
- Mesoblast Limited
- Millennium Pharmaceuticals, Inc.
- MSM Protein Technologies, Inc.
- Neopharm Ltd.
- Novartis AG
- Omni Bio Pharmaceutical Inc.
- Pharmicell Co., Ltd.
- R-Tech Ueno, Ltd.
- REGiMMUNE Corporation
- Rigel Pharmaceuticals, Inc.
- Sarepta Therapeutics, Inc.
- Seattle Genetics, Inc.
- Sigmoid Pharma Limited
- Spherium Biomed S.L.
- Targazyme, Inc.
- Therapix Biosciences Ltd
- Tobira Therapeutics, Inc.
- Xenikos B.V.
- Graft Versus Host Disease (GVHD) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- abatacept - Drug Profile
- AbGn-168H - Drug Profile
- aldesleukin - Drug Profile
- Alecmestencel-L - Drug Profile
- Alpha-1 Antitrypsin - Drug Profile
- alpha-1 proteinase inhibitor (human) - Drug Profile
- ALXN-1007 - Drug Profile
- anti-thymocyte globulin (rabbit) - Drug Profile
- Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile
- Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile
- ApoCell - Drug Profile
- ATIR-101 - Drug Profile
- BCT-100 - Drug Profile
- begelomab - Drug Profile
- Biologics for Graft Versus Host Disease - Drug Profile
- bortezomib - Drug Profile
- BPX-501 - Drug Profile
- brentuximab vedotin - Drug Profile
- budesonide - Drug Profile
- cannabidiol - Drug Profile
- Cell Therapy for Autoimmune Diseases and GVHD - Drug Profile
- Cell Therapy for Graft Versus Host Disease - Drug Profile
- Cell Therapy for Graft Versus Host Disease - Drug Profile
- Cell Therapy for Graft Versus Host Disease - Drug Profile
- Cell Therapy for Graft versus Host Disease - Drug Profile
- Cell Therapy for Graft Versus Host Disease - Drug Profile
- Cell Therapy for Graft Versus Host Disease and Multiple Myeloma - Drug Profile
- cenicriviroc mesylate - Drug Profile
- CLBS-03 - Drug Profile
- CRCBT-080004 - Drug Profile
- cyclosporine IR + cyclosporine CR - Drug Profile
- CYP-001 - Drug Profile
- defibrotide - Drug Profile
- Drugs for Acute and Chronic GVHD - Drug Profile
- erismodegib - Drug Profile
- F-652 - Drug Profile
- Fc-Alpha-1 Antitrypsin - Drug Profile
- FcAAT-2 - Drug Profile
- FcAAT-3 - Drug Profile
- Ha-7 - Drug Profile
- ibrutinib - Drug Profile
- ImmuneSafe - Drug Profile
- Immunocellgram for Graft Versus Host Disease - Drug Profile
- IMO-8400 - Drug Profile
- inolimomab - Drug Profile
- IT-603 - Drug Profile
- IT-901 - Drug Profile
- KD-025 - Drug Profile
- KY-1005 - Drug Profile
- MesoStem - Drug Profile
- MGD-010 - Drug Profile
- milatuzumab - Drug Profile
- Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile
- MSM-707 - Drug Profile
- MultiStem - Drug Profile
- natalizumab - Drug Profile
- Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile
- panobinostat - Drug Profile
- ponesimod - Drug Profile
- Preimplantation Factor - Drug Profile
- PRO-140 - Drug Profile
- Protein to Activate Toll-Like Receptor 5 for Infectious Disease and Graft Versus Host Disease - Drug Profile
- Recombinant HIV Gp120 Protein for GvHD And Autoimmune Disorders - Drug Profile
- Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis - Drug Profile
- Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease - Drug Profile
- remestemcel-L - Drug Profile
- RGI-2001 - Drug Profile
- RO-2959 - Drug Profile
- RTU-009 - Drug Profile
- Small Molecule for Graft Versus Host Disease, Hemophagocytic Lymphohistiocytosis and Autoimmune Disorders - Drug Profile
- Small Molecule to Inhibit Protein Kinase C Theta for Autoimmune Disorders - Drug Profile
- Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia - Drug Profile
- Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile
- SP-12008 - Drug Profile
- Substance X - Drug Profile
- T-Guard - Drug Profile
- TZ-101 - Drug Profile
- Graft Versus Host Disease (GVHD) - Recent Pipeline Updates
- Graft Versus Host Disease (GVHD) - Dormant Projects
- Graft Versus Host Disease (GVHD) - Discontinued Products
- Graft Versus Host Disease (GVHD) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2015
- Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Number of Products under Investigation by Universities/Institutes, H2 2015
- Comparative Analysis by Late Stage Development, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Development, H2 2015
- Comparative Analysis by Unknown Stage Development, H2 2015
- Products under Development by Companies, H2 2015
- Products under Development by Companies, H2 2015 (Contd..1)
- Products under Development by Companies, H2 2015 (Contd..2)
- Products under Development by Companies, H2 2015 (Contd..3)
- Products under Investigation by Universities/Institutes, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Actelion Ltd, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Adienne Pharma & Biotech, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Apceth GmbH & Co. KG, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Athersys, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Limited, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Biogen, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Caladrius Biosciences, Inc. , H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Cell2B S.A. , H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by CytoDyn Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Enlivex Therapeutics Ltd, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Idera Pharmaceuticals, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by ImmuNext, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Immunomedics, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Jazz Pharmaceuticals Plc, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corporation, LLC, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma B.V., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Kymab Limited, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Limited, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by MSM Protein Technologies, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Neopharm Ltd., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Omni Bio Pharmaceutical Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co., Ltd., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by R-Tech Ueno, Ltd., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corporation, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Limited, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Spherium Biomed S.L., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Targazyme, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Therapix Biosciences Ltd, H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Tobira Therapeutics, Inc., H2 2015
- Graft Versus Host Disease (GVHD) - Pipeline by Xenikos B.V., H2 2015
- Assessment by Monotherapy Products, H2 2015
- Assessment by Combination Products, H2 2015
- Number of Products by Stage and Target, H2 2015
- Number of Products by Stage and Mechanism of Action, H2 2015
- Number of Products by Stage and Route of Administration, H2 2015
- Number of Products by Stage and Molecule Type, H2 2015
- Graft Versus Host Disease (GVHD) Therapeutics - Recent Pipeline Updates, H2 2015
- Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2015
- Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..1), H2 2015
- Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..2), H2 2015
- Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..3), H2 2015
- Graft Versus Host Disease (GVHD) - Discontinued Products, H2 2015
- List of Figures
- Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2015
- Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Number of Products under Investigation by Universities/Institutes, H2 2015
- Comparative Analysis by Late Stage Development, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Products, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Top 10 Targets, H2 2015
- Number of Products by Stage and Top 10 Targets, H2 2015
- Number of Products by Top 10 Mechanism of Actions, H2 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
- Number of Products by Top 10 Routes of Administration, H2 2015
- Number of Products by Stage and Top 10 Routes of Administration, H2 2015
- Number of Products by Top 10 Molecule Types, H2 2015
- Number of Products by Stage and Top 10 Molecule Types, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015’, provides an overview of the Graft Versus Host Disease (GVHD)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Graft Versus Host Disease (GVHD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Graft Versus Host Disease (GVHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Graft Versus Host Disease (GVHD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBookOther tasks
;